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Innate immunity plays a crucial role in the pathogenesis of type 2 diabetes and
related complications. Since the toll-like receptors (TLRs) are central to innate
immunity, it appears that they are important participants in the development and
pathogenesis of the disease. Previous investigations demonstrated that TLR2
homodimers and TLR2 heterodimers with TLR1 or TLR6 activate innate immunity
upon recognition of damage-associated molecular patterns (DAMPs). Several DAMPs
are released during type 2 diabetes, so it may be hypothesized that TLR2 is
significantly involved in its progression. Here, we review recent data on the
important roles and status of TLR2 in type 2 diabetes and related complications.
Keywords: Type 2 diabetes, TLR2, Complication, Innate immunity, DAMP, PAMP,
MYD88, Activator protein 1, NF-kB, Leucine-rich repeatsBackground
Type 2 diabetes, also referred to as adult-onset diabetes or as non-insulin-dependent
diabetes mellitus (NIDDM) is increasingly common [1, 2]. The heightened levels of blood
glucose are associated with several complications, including nerve damage (neuropathy),
which is caused by injury to the walls of the capillaries that nourish the nerves and results in
tingling, numbness, burning or pain [3, 4]. Nephropathy is also associated with injuries to
the glomeruli [5]. Eye damage or retinopathy is induced by glucose-related damage to the
blood vessels of the retina [6–8]. Type 2 diabetes correlates significantly with cardiovascular
disease, including heart attack, angina, stroke and atherosclerosis. Moreover, investigations
have shown a link between type 2 diabetes and brain diseases, such as mild cognitive impair-
ment, Alzheimer’s disease and vascular dementia [9]. Other complications include periodon-
titis [10, 11], cystic fibrosis [12], hypertension [13] and hearing impairment [14].
The parameters of innate immunity are associated with type 2 diabetes and its com-
plications [15, 16]. Therefore, it has been hypothesized that the disease is immune
dependent [16, 17]. For instance, in cases of type 2 diabetes, immune cells produce
inappropriate levels of inflammatory cytokines, which may have a deleterious effect on
the pathogenesis of type 2 diabetes [18]. Elevated serum levels of innate immunity infla-
mmatory cytokines such as IL-6 [19], IL-18 [20] and TNF-α [19] have been reported for
subjects with type 2 diabetes and related complications.
Several cross-sectional studies also confirmed the relationship between innate immunity
and type 2 diabetes. For instance, studies were made of non-diabetic subjects and patients
with type 2 diabetes determined as impaired glucose tolerance or impaired fasting glucose.
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concentration, circulating triglyceride level, and BMI and waist circumference measure-
ments; and negatively correlated with HDL concentration [21]. Additionally, it has been
documented that exercise can improve type 2 diabetes complications through its immuno-
modulatory effects [22].
Although a significant relationship between innate immunity and type 2 diabetes has
been confirmed, it has yet to be clarified if innate immunity activation is a major mech-
anism in the induction of type 2 diabetes or if the disease activates innate immunity. It
seems that it is mutual (Fig. 1), so evaluation of innate immunity receptors and their
signaling molecules should our knowledge of the condition and relationship.
Toll-like receptors (TLRs) are the innate immune cell receptors. They play pivotal roles
in the recognition of damage-associated molecular patterns (DAMPs), which occur during
type 2 diabetes. Their recognition leads to several functions of innate immune cells,
including phagocytosis [23], cytokine production [24], and expression of co-stimulatory
molecules [25] and adhesion molecules [26, 27].
Toll-like receptor 2 (TLR2) plays significant roles in the induction of innate immune
cells through a MYD88-dependent pathway [28, 29]. Interestingly, there is some evidence
that confirms the suppressive roles of TLR2 and ligand interactions on immune responsesFig. 1 There is a mutual avenue between type 2 diabetes and innate immunity. Type 2 diabetes can
activate innate immunity and its pathogenesis can be accelerated by activated innate immunity.
CRP: C-reactive protein, SAP: Serum amyloid protein
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related diseases, including type 2 diabetes. Accordingly, the altered expression and
functions of TLR2 and its intracellular molecular signaling may be associated with the
mechanisms that result in the progression and pathogenesis of type 2 diabetes and its
related complications.Toll-Like Receptor 2
TLR2 (TIL4, CD282) was identified and characterized in 1998 [31]. It is an innate
immune cell receptor that recognizes several pathogen-associated molecular patterns
(PAMPs) and DAMPs and subsequently activates MYD88-dependent intracellular
signaling [29]. Chromosome 4 (4p32) is the location of the TLR2 gene. This molecule
is a type I transmembrane protein that has a similar structure to other TLRs, consist-
ing of the following domains from N-terminal to C-terminal: extracellular leucine-rich
repeat (LRR) domains; a transmembrane domain; and a toll/interleukin-1 receptor
(TIR) domain. TLR2 is expressed in several immune cell types, including macrophages
and dendritic cells, and non-immune cell types, including endothelial cells, epithelial
cell lines and hepatocytes [32, 33].
TLR2 recognizes its ligands in both homodimer and heterodimer (with TLR1 or 6) forms
[34]. In its homodimer form, it recognizes lipopolysacharide (LPS), porins, lipoprotein,
lipoteichoic acid, bacterial peptidoglycan, viral hemagglutinin and glycoproteins. In its
TLR2/1 heterodimer form, it recognizes bacterial triacylated lipopeptides and synthetic
triacylated lipopeptide (Pam3CSK4) [35], and in its TLR2/6 heterodimer, it recognizes
bacterial diacylated lipopeptides and lipoteichoic acid [36]. As mentioned previously, TLR2
also recognizes some DAMPs as endogenous ligands, including human glycosaminoglycan
hyaluronan [37], β-defensin-3, heat shock proteins and high mobility group box 1 protein,
some of which are released during inflammatory diseases like type 2 diabetes [30, 38–40].
TLR2–ligand interactions lead to the activation of MAPK and MYD88-dependent
signaling pathways (Fig. 2) [41, 42]. Although MYD88-dependent signaling pathway ac-
tivation results in the phosphorylation and activation of pro-inflammatory transcription
factors, such as IRF3, IRF7, AP-1 and NF-kB, it also induces the PI3K/AKT pathway,
which leads to upregulation of IL-10, and activates SOCS proteins [43]. IL-10 is a major
anti-inflammatory cytokine [44]. SOCS proteins also suppress MAPK and JAK–STAT
signaling pathways [45]. Therefore, it appears that TLR2-ligand interaction leads to
either activation or suppression of immune responses [46, 47].
The principal mechanisms causing the activation or suppression of immune
responses by TLR2 are unclear, but it has been hypothesized that the TLR2 ligand con-
centration may be the determining factor.Type 2 Diabetes And TLR2
DAMPs are endogenous molecules that are produced and released by several cell
systems during inflammation or infection [48, 49]. They can also be released during
type 2 diabetes [50]. Both can be recognized by TLR2, leading to the either activation
or suppression of immune cells. It has been documented that inflammation is a major
cause of pancreatic beta cell dysfunction in type 2 diabetes [51, 52]. Therefore, the
inflammatory effects of TLR2-ligand interaction may be an important factor in type 2
Fig. 2 Following TLR2-ligand interaction a signaling pathway is started using MYD88 as an adaptor
molecule. The signaling pathway leads to the activation of several transcription factors, including NF-kB,
MAPK and AP-1, and subsequently cell activation. Adapted from Bagheri et al. [29]
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related ligands results in the activation of macrophages and the production of IL-1 and
IL-6 as pro-inflammatory cytokines that contribute to islet inflammation [51].
Several studies confirmed the important roles played by reactive oxygen species (ROS) in
the pathogenesis of type 2 diabetes. Interestingly, activation of TLR2 by zymosan leads to
ROS production by neutrophils in a manner dependent on TLR2 NADPH oxidase but not
dependent on MAPK [53]. Hyperglycemia and chronic periodontitis also lead to upregula-
tion of TLR2 in the gingival tissue of type 2 diabetes patients [54]. Interestingly, it has been
demonstrated that insulin suppresses the expression of TLR2 at the mRNA level, possibly
via downregulation of PU.1 [55]. Kuzmicki et al. revealed that the gestational diabetes
patients had significantly higher TLR2 expression than pregnant women with normal
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exhibited normal glucose tolerance but later developed gestational diabetes when compared
to the women who remained normoglycemic [56]. Ahmad et al. demonstrated that the
expression levels of TLR2 were upregulated in obese individuals [57]. Additionally, they
showed that obese type 2 diabetes patients had higher expressions of TLR2 in comparison
to obese patients without type 2 diabetes [57]. The phagocytic cells of type 2 diabetes
patients have also upregulated TLR2 [58].
Another study also identified that TLR2 not only participates in the development of
type 2 diabetes but is also involved in the pathogenesis of related vascular complications
[59]. Moreover, via upregulation of IL-6 and osteopontin, TLR2 causes impaired insulin-
mediated brain activities, which are an early step in the development toward type 2 dia-
betes [60]. Duarte et al. revealed higher mRNA levels of TLR2 in gingival biopsies from
type 2 diabetes patients with chronic periodontitis in comparison to periodontally healthy
patients [61]. Thus, it appears that the upregulation of TLR2 is a marker of type 2 diabetes
rather than a marker of periodontitis. Rojo-Botello et al. also confirmed this result [62].
Another study identified that free fatty acids and high glucose levels upregulate the
expression of TLR2 and TLR6, which resulted in increased activity of monocytes and
increased production of superoxides, which are released in an NF-kB-dependent manner
[63]. Ehses et al. also reported that a high-fat diet was unable to induce insulin resistance
and beta cell dysfunction in TLR2-deficient mice [64]. Free fatty acids also play important
roles in the induction of inflammation in pancreatic beta cells via TLR2 [65]. Interestingly,
another study showed that not only TLR2 has been more highly expressed on the immune
cells of type 2 diabetes patients than on those of healthy subjects, but also the levels of
TLR2 ligands, including hyaluronan, HSP60, HSP70, HMGB1 and endotoxin, were higher
[66]. TLR2 inhibition using a TLR2 antisense oligonucleotide (ASON) leads to recovery of
insulin sensitivity and signaling in muscle and white adipose tissue of mice that were fed a
high-fat diet [67]. It has also been documented that oxidized LDL, which is produced dur-
ing type 2 diabetes, induced expression of TLR2 in macrophages [68]. The expression of
TLR2 on the monocytes of obese women is also higher [68].
TLR2 also recognizes PAMPs such as exogenous microbial ligands, so it may be hypo-
thesized that microbial infections could be important factors in the development of type 2
diabetes and may also participate in the pathogenesis of the disease. Interestingly, a study by
Ajuwon et al. revealed that peptidoglycan derived from Staphylococcus aureus resulted in
elevated TLR2 expression on the 3 T3-L1 adipocytes cell lines [69]. Chen et al. identified
that treatments with agents that improve glycemic control are associated with decreased
expressions of TLR2 and its related intracellular signaling molecules [70]. Previous studies
demonstrated that decreased methylation is associated with higher expression of the genes
[71]. Accordingly, CpGs methylation in the promoter of the TLR2 gene was significantly
decreased in type 2 diabetes patients in comparison to the levels for the controls [72].
As mentioned in the previous section, TLR2 is also able to suppress immune cells through
unknown mechanisms. A few studies demonstrated that TLR2 expression decreased during
type 2 diabetes. For instance, a study by Cortez-Espinosa et al. showed that the percentage of
TLR2-positive monocytes decreased in type 2 diabetes patients with poor glycemic control
when compared to patients with appropriate glycemic control [73]. Another study revealed
that although type 2 diabetes patients had higher serum levels of IL-6, the mRNA levels of
TLR2 were lower than in healthy subjects [74]. Interestingly, their results, which were
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pression of TLR2 [74]. High doses of insulin (100 IU/ml), such as those seen in cases of type
2 diabetes, also increased IL-6 and decreased TLR2 expression [74]. In an in vitro study, it
was shown that TLR4 but not TLR2 interaction with corresponded ligands leads to pancre-
atic beta cell apoptosis [75]. S6K1 plays key roles in driving insulin resistance and the induc-
tion of type 2 diabetes [76]. Kim et al. found that upregulation of S6K1 causes a significant
reduction in NF-kB and AP-1 activities, which are induced by TLR2–ligand interactions [77].
Since more than 90 % of studies reported that TLR2 is positively associated with type 2
diabetes and its complications, it seems that the inflammatory effects of TLR2 during the
condition are predominant. Collectively, it appears that TLR2 plays remarkable roles in
the development of type 2 diabetes and related complications. Therapeutic approaches
involving modulation of the expression of TLR2 and related signaling molecules could be
considered as novel approaches for the treatment of type 2 diabetes.
There have not been many studies on the variation of the TLR2 gene in type 2
diabetes are rare. Liu et al. reported on the low frequency of TLR2 Arg677Trp and
Arg753Gln polymorphisms in type 2 diabetes patients in the Chinese Han population
[78]. Another study showed that the TLR2 R753Q polymorphism was not associated
with type 2 diabetes in Mexican population [79]. Further studies need to be done to
find the relationship between genetic variations and the diseases.
Other TLRs like TLR3 and 4 also play key roles in the induction of this disease. We
discussed the roles played by TLR3 in its development in our previous review [80]. Our
research confirmed that TLR4 can also participate in its pathogenesis [81]. TLR3 and
TLR4 use another signaling pathway, the TRIF-dependent pathway, which may be im-
portant in the development of type 2 diabetes. Thus, it seems that TLR2 is not a unique
innate immunity receptor involved in the development of the disease.
Conclusion
TLR2 plays crucial roles in the initiation and pathogenesis of type 2 diabetes and related
complications. Downregulation of TLR2 can be considered as a novel approach for the
treatment of these conditions. Of particular interest in such research are these points:
TLR2 is upregulated in several tissues that are affected by adult-onset type 2 diabetes
and the gestational version of the disease.
1. TLR2 induces the production of several molecules including ROS and pro-inflammatory
cytokines, which contribute to the worsening type 2 diabetes and related complications.
2. The expression of TLR2 positively correlates with elevated serum levels of free fatty
acids and glucose as well as obesity.
3. Several exogenous and endogenous ligands induce the activation of immune cells and
the dysfunction of pancreatic beta cells in a TLR2-initiated pathway-dependent manner.
4. Different genetic variations and methylation may play key roles in the upregulation
of TLR2 in type 2 diabetes patients.
5. PAMPs participate in the activation of TLR2-initiated pathways, so it may be
hypothesized that infection can be considered a crucial candidate for the
development of type 2 diabetes and related complications.
6. Upregulation of insulin is an important mechanism that suppresses the expression
of TLR2.
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